Literature DB >> 15557524

Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients.

Boby V Maramattom1, Eelco F M Wijdicks.   

Abstract

Neurotoxicity associated with calcineurin inhibitors cyclosporin A and tacrolimus is established. Sirolimus is a new agent related to tacrolimus, but its mechanism of action differs. The authors reviewed 202 transplant recipients treated with sirolimus from 2001 to 2004. They found no evidence of neurotoxicity with sirolimus therapy for up to 18 months (range, 15 days to 3 years). Sirolimus could be considered a substitute immunosuppressant for patients with cyclosporin A or tacrolimus neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557524     DOI: 10.1212/01.wnl.0000144351.63740.81

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  Notes on the kidney and its diseases for the neurologist.

Authors:  Michael S Zandi; Alasdair J Coles
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-05       Impact factor: 10.154

2.  Immunophyllin ligands show differential effects on alcohol self-administration in C57BL mice.

Authors:  Thomas Beresford; Tina Fay; Natalie J Serkova; Peter H Wu
Journal:  J Pharmacol Exp Ther       Date:  2012-02-28       Impact factor: 4.030

Review 3.  Neurologic Complications of Commonly Used Drugs in the Hospital Setting.

Authors:  Elliot T Dawson; Sara E Hocker
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

Review 4.  Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Krista Kuitwaard; Pieter A van Doorn
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

5.  Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin.

Authors:  Jaime A Yáñez; M Laird Forrest; Yusuke Ohgami; Glen S Kwon; Neal M Davies
Journal:  Cancer Chemother Pharmacol       Date:  2007-03-29       Impact factor: 3.333

6.  No major neurologic complications with sirolimus use in heart transplant recipients.

Authors:  Diederik van de Beek; Walter K Kremers; Sudhir S Kushwaha; Christopher G A McGregor; Eelco F M Wijdicks
Journal:  Mayo Clin Proc       Date:  2009-04       Impact factor: 7.616

7.  Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy.

Authors:  Ha Na Woo; Hye Kyung Chung; Eun Jin Ju; Joohee Jung; Hye-Won Kang; Sa-Won Lee; Min-Hyo Seo; Jin Seong Lee; Jung Shin Lee; Heon Joo Park; Si Yeol Song; Seong-Yun Jeong; Eun Kyung Choi
Journal:  Int J Nanomedicine       Date:  2012-04-27

Review 8.  The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence.

Authors:  Goran B Klintmalm; Björn Nashan
Journal:  J Transplant       Date:  2014-02-25

9.  Neurotoxicity of Paclitaxel and Rapamycin in a Rat Model with Transient Blood-Brain Barrier Opening.

Authors:  Won-Sang Cho; Jung Hoon Choi; O-Ki Kwon
Journal:  J Korean Neurosurg Soc       Date:  2022-02-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.